A flexible stochastic curtailing procedure for the log-rank test

被引:6
作者
Bautista, OM
Bain, RP
Lachin, JM
机构
[1] George Washington Univ, Dept Stat, Biostat Ctr, Rockville, MD 20852 USA
[2] Merck Res Labs, Blue Bell, PA USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 05期
关键词
B-value; conditional power; log-rank test; stochastic curtailing; survival analysis;
D O I
10.1016/S0197-2456(00)00068-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
For safety and ethical reasons, a data monitoring committee of a clinical trial may wish to assess the futility of continuing a trial if the currently available data at an interim look show no beneficial effect due to treatment, especially when accompanied by mounting evidence of treatment emergent adverse effects. Stochastic curtailing whereby conditional power is evaluated given currently observed data is one way of evaluating futility. In clinical trials that look at "time-to-event" as the primary outcome, difference between treatment groups with respect to the primary outcome is commonly evaluated using the log-rank test. Although the unconditional power function for the log-rank test has been described previously, its conditional power has not been widely investigated. We describe a method for evaluating conditional power when the log-rank test is used to assess the difference between the survival distributions of two treatment groups with respect to some failure-time outcome. The method is useful under a wide range of assumptions regarding the underlying survival distribution, patient entry distribution, losses to follow-up, and (if applicable) noncompliance, drop-ins, lag in treatment effect, and stratification. This level of applicability is attained by generalizing a flexible Markov chain approach to unconditional power computation, described previously, to compute conditional power. (C) Elsevier Science Inc. 2000.
引用
收藏
页码:428 / 439
页数:12
相关论文
共 29 条
[1]  
ANDERSEN PK, 1987, CONTROL CLIN TRIALS, V8, P67
[2]  
[Anonymous], CALCUTTA STAT ASS B
[3]   Multiple imputation for early stopping of a complex clinical trial [J].
Betensky, RA .
BIOMETRICS, 1998, 54 (01) :229-242
[4]   POWER ESTIMATION FOR RANK-TESTS USING CENSORED-DATA - CONDITIONAL AND UNCONDITIONAL [J].
CANTOR, AB .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :462-473
[5]   STATISTICAL ASPECTS OF EARLY TERMINATION IN THE BETA-BLOCKER HEART ATTACK TRIAL [J].
DEMETS, DL ;
HARDY, R ;
FRIEDMAN, LM ;
LAN, KKG .
CONTROLLED CLINICAL TRIALS, 1984, 5 (04) :362-372
[6]  
Fleming T. R., 1991, COUNTING PROCESSES S
[7]  
Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204
[8]   PLANNING SIZE AND DURATION OF A CLINICAL TRIAL STUDYING TIME TO SOME CRITICAL EVENT [J].
GEORGE, SL ;
DESU, MM .
JOURNAL OF CHRONIC DISEASES, 1974, 27 (1-2) :15-24
[9]   AN AID TO DATA MONITORING IN LONG-TERM CLINICAL-TRIALS [J].
HALPERIN, M ;
LAN, KKG ;
WARE, JH ;
JOHNSON, NJ ;
DEMETS, DL .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :311-323
[10]   DESIGNING CLINICAL-TRIALS WITH ARBITRARY SPECIFICATION OF SURVIVAL FUNCTIONS AND FOR THE LOG RANK OR GENERALIZED WILCOXON TEST [J].
HALPERN, J ;
BROWN, BW .
CONTROLLED CLINICAL TRIALS, 1987, 8 (03) :177-189